Point mutations in FUS cause amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease-but do they do that by a loss of the protein's normal function, or by endowing it with novel toxic functions, or both? In this issue of The EMBO Journal, Scekic-Zahirovic et al (2016) report that mutant FUS, but not the complete loss of FUS, triggers motor neuron degeneration in mice, arguing for a toxic gain-of-function mechanism. (Mackenzie et al, 2010). Based on this neuropathology, it is thought that loss of either TDP-43 or FUS from the nucleus or aberrant function of TDP-43 or FUS in the cytoplasm, or a combination of both, is toxic to neurons (Ling et al, 2013).
Point mutations in FUS cause amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease-but do they do that by a loss of the protein's normal function, or by endowing it with novel toxic functions, or both? In this issue of The EMBO Journal, Scekic-Zahirovic et al (2016) report that mutant FUS, but not the complete loss of FUS, triggers motor neuron degeneration in mice, arguing for a toxic gain-of-function mechanism.
See also: J Scekic-Zahirovic et al (May 2016) P atients who suffer from ALS or a related disorder, frontotemporal dementia (FTD), have characteristic protein aggregates in their brains. These aggregates are found in neuronal and glial cells and contain DNA/RNA-binding proteins, most notably TDP-43 or, less frequently, FUS (Mackenzie et al, 2010) . Both TDP-43 and FUS are usually located in the cell nucleus, where they regulate transcription and splicing of numerous target genes (Lagier-Tourenne et al, 2012) . However, in ALS/FTD patients, TDP-43 or FUS is no longer found in the nucleus and instead accumulates in cytoplasmic protein aggregates (Mackenzie et al, 2010) . Based on this neuropathology, it is thought that loss of either TDP-43 or FUS from the nucleus or aberrant function of TDP-43 or FUS in the cytoplasm, or a combination of both, is toxic to neurons (Ling et al, 2013) .
To solve this interesting loss-of-function versus gain-of-function puzzle, three ALS research groups teamed up to study novel FUS mouse models that either express no FUS at all (Fus À/À ) or have cytoplasmically mislocalized FUS instead of nuclear FUS (Fig 1) . To generate the latter model, they genetically disrupted the protein's nuclear localization signal (NLS), which is located at the very C-terminus and is required for proper nuclear import (Dormann et al, 2010) . Interestingly, the NLS of FUS is also mutated or truncated in some ALS patientsthese patients show cytosolic FUS accumulation and suffer from early onset ALS (Kwiatkowski et al, 2009; Waibel et al, 2013 (Sharma et al, 2016) . They too found that mutant cytoplasmic FUS causes agedependent motor neuron degeneration, whereas wild-type FUS or FUS knockout leaves motor neurons unaffected.
How exactly cytoplasmic FUS kills motor neurons still remains to be unraveled. First hints from Scekic-Zahirovic et al (2016) indicate that it may alter the subcellular localization of FUS interaction partners and may elicit cellular stress. Another possibility is that elevated FUS in the cytosol abnormally augments the cytosolic functions of FUS in mRNA transport, stabilization, and local translation (Bowden & Dormann, 2016) . Alternatively, it may drive liquid-to-solid phase transition and thus "solidification" of FUS-containing RNA granules over time (Patel et al, 2015 ) have FUS in the cytosol rather than in the nucleus. This causes a nuclear LOF and postnatal death, but also gain-of-function (GOF) changes that lead to motor neuron degeneration. Motor neuron apoptosis can be rescued by motor neuron-specific reversal of the NLS deletion (ChAT-Cre Fus The EMBO Journal FUScinating insights Dorothee Dormann
